On Demand Webinar

Effective Preclinical Solutions to Tackle Oncology Drug Resistance

Cancer drug resistance can be multifaceted which can be challenging to understand, model and target, which is why it is an area of high unmet medical need. In this webinar we outline the solutions available to reflect the clinical situation with the most effective preclinical tools, exploring both intrinsic and acquired resistance.

Watch Now

You'll Learn About:

• Background on the challenges of cancer drug resistance and the evolving landscape of clinical need.
  
  
• Which preclinical models and strategies to implement for ongoing efforts in drug discovery and development tackling resistance.
  
  
• Examples of resistance to targeted therapy and immunotherapeutics with key features, challenges, opportunities and solutions.

Watch Now

Watch to learn about the advantages of taking an integrated solutions approach to addressing cancer drug resistance.

About The Presenter:

Rajendra Kumari, PhD, Executive Director, Integrated Solutions, Crown Bioscience

As Executive Director of Integrated Solutions within the Commercial and Strategic Development team, Rajendra leads the focus of cross-disciplinary solutions for drug discovery and development. She has over 20 years of oncology research experience with a Ph.D. in Molecular Pharmacology from the University of Leicester (UK). Prior to joining Crown Bioscience, Rajendra held post doctoral fellowships and Assistant Professor position in the Division of Preclinical Oncology within the Medical School, University of Nottingham where she developed in vitro and in vivo preclinical models including patient-derived systems and imaging capabilities. Rajendra also co-founded PRECOS Ltd in 2010, serving as COO and then following merger with Crown Bioscience, as CSO and General Manager for Crown Bioscience UK. In 2018, Rajendra became Global Head of Scientific Communications for all platforms at Crown Bioscience Inc., working closely with multiple divisions and global departments to support the commercialization of R&D activity and capabilities. Rajendra is a member of the AACR and BACR and has authored over 40 abstracts and publications.